Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 30 (TRAV30) encodes a variable region segment of the TCR alpha chain, which is used during V(J) recombination in the thymus to generate the antigen specificity of individual T cells. The TCR complex, consisting of alpha and beta chains (or, less commonly, gamma and delta), recognizes specific peptide antigens presented on major histocompatibility complex (MHC) molecules on antigen-presenting cells, playing a central role in the adaptive immune response. The diversity arising from segments like TRAV30 enables the immune system to recognize a wide array of antigens. TRAV30, as a germline-encoded V segment, is part of the enormous combinatorial diversity that determines the specificity of each T cell clone.
Not applicable for TRAV30 directly. For drugs targeting the TCR complex or T cells: Inhibition or activation of T cell activation and proliferation via TCR complex signaling modulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 30 (TRAV30).